Synta gets FDA fast-track status for lung cancer drug; Bullet Biotechnology closes Series A;

@FierceBiotech: Trending now: Biotech R&D spending roars ahead as Big Pharma grimly holds the line. ICYMI yesterday | Follow @FierceBiotech

@JohnCFierce: Delcath gets a CRL, a demand for a new trial, some other hurdles, and fires its CEO. Busy day. Release | Follow @JohnCFierce

@EmilyMFierce: NIH partners with Eli Lilly, others on rare diseases. Article | Follow @EmilyMFierce

> The FDA has granted Synta Pharmaceuticals ($SNTA) fast-track designation for ganetespib, the company's lead Hsp90 inhibitor drug candidate, to use alongside docetaxel to improve overall survival in patients with metastatic non-small cell lung adenocarcinoma. Release

> Bullet Biotechnology has closed a Series A financing, bringing the total amount raised since the company's founding in September 2011 to $2.5 million. Release

> Sangamo BioSciences ($SGMO) presented new data for its ZFP Therapeutic, SB-728-T, to the treatment of HIV/AIDS at Interscience Conference on Antimicrobial Agents and Chemotherapy on Sept. 11. A single infusion of SB-728-T showed sustained functional control of the virus and suppression of viral load in the blood, according to the data. Release

> The European Medicines Agency has granted orphan drug designation for GlycoMimetics' GMI-1070 to treat vaso-occlusive crisis (VOC), a common painful complication of sickle cell disease. Release

Medical Device News

@FierceMedDev: InVivo slides again as CFO bolts, spinal study pends. ICYMI yesterday | Follow @FierceMedDev

@DamianFierce: Covidien projects a modest 2014, its first full year with no pharma revenue. Report | Follow @DamianFierce

@MarkHFierce: We have a new round of stories at FierceDiagnostics. Check them out | Follow @MarkHFierce

@MichaelGFierce: This week, in life sciences hiring: Ex-Bausch + Lomb CEO takes helm at Forest Labs... and more. Chutes & Ladders | Follow @MichaelGFierce

> Foundation Medicine eyes $92M in IPO. Report

> Study: Health reform law will produce major gains for some device companies. Article

> Medicare Dx test coverage gets revamp in new U.S. House bill. Item

Pharma News

@FiercePharma: Ruling against GSK's Lovaza fish-oil pill puts hurt on competitor Amarin. Story | Follow @FiercePharma

@EricPFierce: South Africa's Aspen says manufacturing assets it is getting from GSK, Merck part of global push. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI: Is J&J's manufacturing any better off since it pledged to keep closer oversight? Second recall in two weeks. Report | Follow @CarlyHFierce

> Lilly files $500M lawsuit against Canada. News

> Germany's Bayer joins crowd of companies under Chinese investigation. More

> J&J trying to drag Boehringer into arbitration over Doxil production lapses. Article

> FDA panel gives 'historic' thumbs-up to Roche's Perjeta in early breast cancer. News

And Finally... For your viewing pleasure, the 6 Most Important Milestones in the History of Drugs by Popular Science.

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.